J Korean Diabetes.  2022 Dec;23(4):230-237. 10.4093/jkd.2022.23.4.230.

Management of Intractable Painful Diabetic Peripheral Neuropathy: The Perspective of a Pain Specialist

• Moon JY

• KMID: 2538092
• DOI: http://doi.org/10.4093/jkd.2022.23.4.230

Abstract

Peripheral neuropathy is one of the most common complications of both type 1 and type 2 diabetes. The most common diabetic neuropathy (DN) is distal symmetric polyneuropathy, with characteristic glove- and stocking-like presentation of distal sensory or motor function loss. Because painful DN is associated with increased mortality and morbidity, early recognition and preventive measures are essential. Nevertheless, diagnosing DN or painful DN is challenging, particularly in patients with early and mild neuropathy, and there is no established gold standard. Furthermore, there is no established DN treatment other than improved glycemic control, and only symptomatic management is available for painful DN. However, thanks to health-conscious living, almost one-third of patients with painful DN derive sufficient pain relief with existing pharmacotherapies. These include antidepressants (tricyclic acid, serotonin-norepinephrine reuptake inhibitor), anticonvulsants (calcium-channel blocker, sodium channel blocker), and others (sarpogrelate). A more precise and distinct symptom profile from patients with painful DN may help identify patients more responsive to one treatment versus another. In addition to pharmacological, physical, cognitive, or educational management for painful DN, large randomized clinical trials are needed to identify the most effective minimally invasive interventions. Transcutaneous electrical nerve stimulation, pain scrambler therapy, sympathetic ganglion block, and botulinum toxin injections have been investigated as alternative therapeutic outcomes.

Keyword

Diabetic neuropathy; Diagnostic challenges; Implications for management; Intervention; Painful diabetic neuropathy; Pharmacological management

Figure

• 

  Fig. 1. Pain scrambler therapy for managing patients with thoracic postherpetic neuralgia.

• 

  Fig. 2. Device for self-noninvasive neuromodulation therapy at home.

Reference

1.Jensen TS., Karlsson P., Gylfadottir SS., Andersen ST., Ben-nett DL., Tankisi H, et al. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain. 2021. 144:1632–45.

2.Zakin E., Abrams R., Simpson DM. Diabetic neuropathy. Semin Neurol. 2019. 39:560–9.

3.Sloan G., Selvarajah D., Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol. 2021. 17:400–20.

4.Herman WH., Petersen M., Kalyani RR. Response to comment on American Diabetes Association. Stan-dards of Medical Care in Diabetes-2017. Diabetes Care. 2017. 40(Suppl 1):S1–35. Diabetes Care 2017;40:e94-5.

5.Abbott CA., Malik RA., van Ross ER., Kulkarni J., Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011. 34:2220–4.

6.Dworkin RH., O'Connor AB., Kent J., Mackey SC., Raja SN., Stacey BR, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013. 154:2249–61.

7.Yagihashi S., Yamagishi S., Wada R. Pathology and patho-genetic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms. Diabetes Res Clin Pract. 2007. 77(Suppl 1):S184–9.

8.Moghtaderi A., Bakhshipour A., Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006. 108:477–81.

9.Snedecor SJ., Sudharshan L., Cappelleri JC., Sadosky A., Mehta S., Botteman M. Systematic review and meta-anal-ysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014. 14:167–84.

10.Yoo H., Park I., Kim DJ., Lee S. Effects of sarpogrelate on microvascular complications with type 2 diabetes. Int J Clin Pharm. 2019. 41:563–73.

11.Snyder MJ., Gibbs LM., Lindsay TJ. Treating painful diabetic peripheral neuropathy: an update. Am Fam Physi-cian. 2016. 94:227–34.

12.Moon JY., Kurihara C., Beckles JP., Williams KE., Jamison DE., Cohen SP. Predictive factors associated with success and failure for Calmare (Scrambler) therapy: a multi-center analysis. Clin J Pain. 2015. 31:750–6.

13.Yoo Y., Lee CS., Kim J., Jo D., Moon JY. Botulinum toxin type A for lumbar sympathetic ganglion block in complex regional pain syndrome: a randomized trial. Anesthesiology. 2022. 136:314–25.